This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant unmet needs that remain across oncology.
We begin with a timely review by Azenkot et al. examining the relationship between acquired immunosuppression and skin cancer risk. As the population of immunosuppressed patients continues to expand, understanding the
mechanisms underlying increased susceptibility to cutaneous malignancies is essential, alongside the importance of prevention, early detection and multidisciplinary care.
Fujii et al. then address the persistent challenges in small bowel adenocarcinoma, a rare but increasingly recognized gastrointestinal malignancy. They outline the limitations of current treatment paradigms, and explore the promise of biomarker-driven approaches. Notably, the emergence of antibody–drug conjugates offers renewed hope in a disease where progress has historically been constrained by its rarity.
Advances in pancreatic cancer care are comprehensively reviewed by Alshwayyat et al., who synthesize current knowledge spanning epidemiology, molecular biology, diagnostics and treatment strategies. Their article highlights the complexity of tumour biology and the ongoing challenges in early detection and therapeutic innovation, while exploring emerging modalities such as immunotherapy, artificial intelligence and novel biomarkers.
Pereira et al. examine the impact of corticosteroid use on outcomes in patients receiving immune checkpoint inhibitors, providing important insights into how timing, dosage and indication can influence therapeutic benefit and reinforcing the need for individualized clinical decision-making.
In the era of precision oncology, targeted therapies continue to redefine treatment landscapes. Pallas et al. present a focused review on HER2-mutant non-small cell lung cancer, highlighting the clinical development and
emerging role of zongertinib, a promising option for a molecularly defined subgroup of patients.
Finally, Soares et al. explore the development of imipridones in diffuse midline glioma, outlining their unique mechanisms of action and future therapeutic potential in this challenging disease.
We hope this issue provides valuable perspectives for clinicians and researchers and supports ongoing efforts to improve outcomes for patients with cancer. The editors of touchREVIEWS in Oncology & Haematology and myself would like to extend our gratitude to all contributing authors for their valuable expertise, to our reviewers for their time and thoughtful insights, and to our Editorial Board and society partners for their continued dedication. We hope this issue provides both inspiration and practical guidance as you navigate the rapidly evolving field of oncology and haematology.
Axel Merseburger
Prof. Dr. med. Axel Stuart Merseburger is a highly experienced urologist with over 21 years of practice. He works at the Department of Urology at the University Hospital Schleswig-Holstein in Lubeck, Germany and specializes in urology and robotic surgery. Dr Merseburger is considered an expert in his field with a wide range of qualifications and achievements. Having studied medicine at top institutions such as the Hannover Medical School and the Harvard Medical School, Dr Merseburger has gained extensive knowledge and expertise. He has completed various fellowships and training, including a scholarship at the Uniformed Services University in Washington and a fellowship at the Henry M Jackson Foundation Center for Prostate Disease Research. Dr Merseburger has published 442 scientific publications, demonstrating his dedication to research and innovation. He has received numerous awards and prizes, including the Werner Staehler Memorial and Urologia Internationalis prizes. With his wealth of experience and expertise, Dr Merseburger is known for his contributions to the field of urology. He is highly regarded for his skills in robotic surgery and his focus on prostate cancer. His dedication to improving patient outcomes and advancing the field of urology makes him a highly respected and trusted doctor. Overall, Prof. Dr. med. Axel Stuart Merseburger is an accomplished uro-urologist who brings knowledge and expertise to his practice. His dedication to research, innovative treatments and patient care makes him a valuable asset to the medical community.
